Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises HAKI Safety AB (publ) in connection with the acquisition of Semmco Group Limited
Mandate

Vinge advises HAKI Safety AB (publ) in connection with the acquisition of Semmco Group Limited

November 19, 2024 M&A Intellectual Property Employment and Benefits

Semmco Group is a UK market-leading manufacturer and supplier of maintenance platforms and stairs for aircraft and trains.

Semmco Group designs and manufactures products that enable safe and efficient maintenance of airplanes, helicopters, and trains. The product range includes specially developed access platforms, steps and docking systems. The customers are primarily international aviation and train companies. Semmco's headquarters and main manufacturing operation are located in Woking, Surrey, England. Manufacturing and sales operation also take place in Arlington, Texas, USA. The markets in the Middle East and Asia are served through a sales office in Dubai, United Arab Emirates.

Vinge's team consisted of Anna Edström, Niklas Törnell, Johan Severinsson (M&A), as well as Lisa Bourghardt (IP) and Karin Hultgren (employment law/personal data).

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

 Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026